Kristin Sauer
Research Subjects
Kristin Sauer has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Eberhard Rabe
Dermatologische Universitätsklinik Bonn
2 shared publications - Markus Stücker
St. Josef-Hospital Bochum, Deutschland
2 shared publications Astrid Riebeling
BSN medical GmbH, Deutschland
1 shared publicationJanet Zowe
Medi SE & Co. KG, Deutschland
1 shared publication- Kristina Hagenström
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
1 shared publication - Luis Möckel
UCB, Monheim am Rhein
1 shared publication
Latest Publications
- 16 November 2026
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 151 (23) , 1302-1308
Venenerkrankungen, Lymphödem und Lipödem im Kontext der Adipositas: Übersicht zur Risikoevidenz und Relevanz der Medizinischen Kompressionstherapie
Zusammenfassung: Venenerkrankungen, Lymphödeme und Lipödeme sind häufige Folgeerkrankungen der Adipositas. Diese Übersichtsarbeit soll (a) Adipositas als Risikofaktor sowie (b) die Bedeutung der medizinischen Kompressionstherapie (MKT) im Management der Adipositas unterstreichen. Grundlage war eine systematische Literaturrecherche in MEDLINE zur Risikoevidenz. Die Bedeutung der MKT wurde aus aktuellen Veröffentlichungen und Leitlinien abgeleitet. (a) Adipositas erhöht das Risiko für Venenerkrankungen (OR: 10,22 [7,67–13,62]), Lymphödem (OR: bis 6,7 [2,1–23,0]) sowie für die Symptomverschlechterung beim Lipödem (BMI, OR: 1,24 [1,19–1,29]). (b) MKT ist im Management dieser Erkrankungen zentral, insbesondere Flachstrick und Medizinisch Adaptive Kompressionssysteme (MAKs). Mit steigender Prävalenz der Adipositas nehmen Häufigkeit und/oder Schweregrad dieser Erkrankungen zu. MKT sollte im Adipositas Disease Management Programm verankert werden.
- 16 November 2026
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 151 (23) , 1302-1308
Venenerkrankungen, Lymphödem und Lipödem im Kontext der Adipositas: Übersicht zur Risikoevidenz und Relevanz der Medizinischen Kompressionstherapie
Zusammenfassung: Venenerkrankungen, Lymphödeme und Lipödeme sind häufige Folgeerkrankungen der Adipositas. Diese Übersichtsarbeit soll (a) Adipositas als Risikofaktor sowie (b) die Bedeutung der medizinischen Kompressionstherapie (MKT) im Management der Adipositas unterstreichen. Grundlage war eine systematische Literaturrecherche in MEDLINE zur Risikoevidenz. Die Bedeutung der MKT wurde aus aktuellen Veröffentlichungen und Leitlinien abgeleitet. (a) Adipositas erhöht das Risiko für Venenerkrankungen (OR: 10,22 [7,67–13,62]), Lymphödem (OR: bis 6,7 [2,1–23,0]) sowie für die Symptomverschlechterung beim Lipödem (BMI, OR: 1,24 [1,19–1,29]). (b) MKT ist im Management dieser Erkrankungen zentral, insbesondere Flachstrick und Medizinisch Adaptive Kompressionssysteme (MAKs). Mit steigender Prävalenz der Adipositas nehmen Häufigkeit und/oder Schweregrad dieser Erkrankungen zu. MKT sollte im Adipositas Disease Management Programm verankert werden.
- Open Access
- 5 October 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (10)
Underprovision of Medical Compression Therapy: Retrospective Analysis Based on Statutory Health Insurance Data on Venous Leg Ulcers, Chronic Venous Disease and Comorbidities
Chronic venous diseases (CVD), including venous leg ulcers (VLU), represent a significant health burden. Despite the central role of compression therapy in current treatment guidelines, recent evidence suggests substantial gaps in provision. A retrospective cohort study was conducted using anonymized claims data from 3.35 million insured individuals. Persons with VLU or CVD in 2017 were observed over 5 years. Compression therapy, comorbidities, antibiotic prescriptions, and physician contacts were analysed. The prevalence was 0.50% for VLU ( n = 16 615) and 7.27% for CVD ( n = 243 681). Across 5 years, 75.85% (VLU) and 53.10% (CVD) received compression therapy. However, 24.15% of persons with VLU were not treated with compression therapy. Persons receiving compression were predominantly female and older (VLU: 74.13 years, 59.56% women; CVD: 68.55 years, 70.86% women), exhibited a higher mean Charlson Comorbidity Index (CCI [95% CI]: VLU 4.09 [4.03–4.15], CVD 2.67 [2.65–2.68] vs. VLU 3.14 [3.05–3.23], CVD 2.12 [2.11–2.14] without compression). In the first year post‐diagnosis, 51.43% VLU persons with compression received antibacterials (vs. 36.28%). The data confirm prior estimates of disease prevalence and highlight a substantial gap in the documented use of guideline‐compliant compression therapy, especially in VLU. High multimorbidity and care intensity underscore the need for better integration of compression therapy in routine practice.
- 5 October 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (10)
Open AccessUnderprovision of Medical Compression Therapy: Retrospective Analysis Based on Statutory Health Insurance Data on Venous Leg Ulcers, Chronic Venous Disease and Comorbidities
Chronic venous diseases (CVD), including venous leg ulcers (VLU), represent a significant health burden. Despite the central role of compression therapy in current treatment guidelines, recent evidence suggests substantial gaps in provision. A retrospective cohort study was conducted using anonymized claims data from 3.35 million insured individuals. Persons with VLU or CVD in 2017 were observed over 5 years. Compression therapy, comorbidities, antibiotic prescriptions, and physician contacts were analysed. The prevalence was 0.50% for VLU ( n = 16 615) and 7.27% for CVD ( n = 243 681). Across 5 years, 75.85% (VLU) and 53.10% (CVD) received compression therapy. However, 24.15% of persons with VLU were not treated with compression therapy. Persons receiving compression were predominantly female and older (VLU: 74.13 years, 59.56% women; CVD: 68.55 years, 70.86% women), exhibited a higher mean Charlson Comorbidity Index (CCI [95% CI]: VLU 4.09 [4.03–4.15], CVD 2.67 [2.65–2.68] vs. VLU 3.14 [3.05–3.23], CVD 2.12 [2.11–2.14] without compression). In the first year post‐diagnosis, 51.43% VLU persons with compression received antibacterials (vs. 36.28%). The data confirm prior estimates of disease prevalence and highlight a substantial gap in the documented use of guideline‐compliant compression therapy, especially in VLU. High multimorbidity and care intensity underscore the need for better integration of compression therapy in routine practice.